The sharpest read is a randomized survival signal without a mechanistically matched anchor, leaving accelerated approval as a high-stakes interpretation call. [1] REGAL is described as an international, open-label, randomized Phase 3 trial of galinpepimut-S maintenance monotherapy versus investigator's choice best available therapy in AML in complete remission after second-line salvage therapy, with the press summary reporting 126 patients, median overall survival of 24 months for GPS versus 14.7 months for standard of care and a statistically significant 41% reduction in risk of death, prompting planned FDA submission in the first half of next year toward potential accelerated approval. Competitive context is crowded but mechanistically distinct, including oral azacitidine noted as approved for AML maintenance, azacitidine and venetoclax combinations described in post-transplant and transplant-ineligible use, and FLT3 inhibitors midostaurin, quizartinib, gilteritinib and sorafenib plus IDH inhibitors ivosidenib and enasidenib described as targeted maintenance options, alongside prior single-arm GPS Phase 2 NCT01266083 in 22 patients in first complete remission. [2][3] No ICER, HTA decision, confidence interval, p-value, safety table, or comparator composition detail is provided to test payer or regulatory durability, and the Phase 3 record is listed as ACTIVE_NOT_RECRUITING with enrollment listed as 127 in one source versus 126 patients in the press summary and 171 versus 116 in other registry extracts. [4][5] No closely comparable precedent exists that shares both WT1 vaccine mechanism and second-remission maintenance versus best available therapy, so the package must be judged on general AML expectations for distinct indications, randomized time-to-event evidence, and standardized biomarker handling rather than on a clean analogue, and the sharpest gap is missing statistical and safety granularity behind a small open-label survival readout. [4][6]
Phase 3 REGAL RCT reports 24 vs 14.7 months median OS and 41% risk reduction in 126 patients, but without CIs, p-values, safety or comparator detail and with ACTIVE_NOT_RECRUITING status.
| Indication | Acute myeloid leukemia |
| Drug | galinpepimut-S |
| Mechanism of Action | WT1-targeting immunotherapeutic cancer vaccine |
| Company | Sellas Life Sciences |
| Trial Phase | Phase 3 |
| Trial Acronym | REGAL |
| NCT ID | NCT04229979 |
| Category | Clinical Trial Event |
| Sub Category | Topline Results Positive |
| Therapeutic Area | Oncology |
| Primary Endpoint | Overall Survival |
| Risk Reduction | 41% |
| Median Overall Survival (GPS arm) | 24 months |
| Median Overall Survival (Control arm) | 14.7 months |
| Patient Population Size | 126 |
| Patient Population | Acute myeloid leukemia patients in second or later remission or in remission and ineligible for an allogeneic stem cell transplant |
| Comparator | Investigator’s choice of the best available treatment |
| Regulatory Pathway | Accelerated pathway, FDA submission in first half of next year |
| Mechanism Detail | Four WT1-derived peptides |
| Adverse Events Profile | Generally well tolerated, predominantly mild to moderate, most commonly local injection site reactions |
Sellas' GPS Vaccine Significantly Improves Survival in AML Phase 3 Trial
Sellas Life Sciences' investigational cancer vaccine, galinpepimut-S (GPS), demonstrated a statistically significant 41% reduction in the risk of death in a Phase 3 REGAL trial for acute myeloid leukemia (AML). The study, involving 126 patients in second or later remission or ineligible for allogeneic stem cell transplant, showed a median overall survival of 24 months for GPS compared to 14.7 months for standard of care. This positive outcome is prompting Sellas to prepare for an FDA submission in the first half of next year, aiming for a potential accelerated approval pathway to address the significant unmet need in this patient population.
- The Phase 3 REGAL trial achieved its primary endpoint, demonstrating a statistically significant 41% reduction in the risk of death for patients treated with galinpepimut-S (GPS). This translated to a median overall survival of 24 months for GPS recipients, a substantial improvement over the 14.7 months observed in the control arm receiving investigator’s choice of best available treatment, highlighting a clinically meaningful benefit for difficult-to-treat AML patients.
- Following these robust Phase 3 results, Sellas Life Sciences is preparing to engage with the FDA to discuss a potential accelerated approval pathway and aims for a submission in the first half of next year. This initiative is driven by the significant unmet need among AML patients in second remission who cannot undergo allogeneic stem cell transplantation, a population facing poor survival outcomes and requiring new, effective treatment approaches.
- Galinpepimut-S (GPS) is an immunotherapeutic cancer vaccine designed to stimulate both CD4+ and CD8+ T cell immune responses against WT1-expressing cancer cells, utilizing four WT1-derived peptides. The treatment was generally well tolerated in the REGAL trial, with treatment-related adverse events predominantly mild to moderate, most commonly presenting as local injection site reactions, indicating a favorable safety profile for this novel approach.
The Critical Unmet Need in Relapsed/Refractory AML
Recent literature on acute myeloid leukemia (AML) centers on older or unfit patients with newly diagnosed AML who are ineligible for intensive chemotherapy, and on biologically high-risk subgroups where response and survival remain poor. Additional focus is directed toward relapsed/refractory disease, post-transplant relapse prevention, and measurable residual disease (MRD)-directed intervention.
Older or unfit patients with newly diagnosed AML ineligible for intensive chemotherapy: Studies evaluated venetoclax combined with hypomethylating agents, oral decitabine/cedazuridine (35 mg/100 mg, days 1-5) plus venetoclax in 28-day cycles, venetoclax plus azacitidine in patients aged 65-74 years in Japan, outcomes in patients ≥80 years old with median age 83 years, outcomes in patients ≥75 years, and frailty stratification using the Clinical Frailty Scale, with median overall survival of 7.6 months for low-frailty patients versus 2.5 months for high-frailty patients.
Secondary, therapy-related, and previously exposed AML with adverse genomics: Populations include secondary AML, therapy-related myelodysplastic syndrome rapidly evolving to acute myeloid leukemia, post-myeloproliferative neoplasm AML, prior hypomethylating agents exposure in 16% and in 47% of cohorts, TP53 mutations and TP53 deletion/mutation, complex karyotype, FLT3-ITD, K/NRAS, and KMT2A rearrangements, with median OS of 2.5 months among patients with TP53-mutated AML and median OS of 7.2 months (95% CI, 3.6-29.9) in secondary AML treated with oral decitabine/cedazuridine plus venetoclax.
Relapsed/refractory AML requiring salvage and bridge to allogeneic transplantation: Evaluations include FLAMSA versus FLAG-IDA as salvage therapy with CR/CRi rates after one cycle of 66.1% vs. 58.3%, patients relapsing after Allo-HCT, primary refractory patients, and venetoclax-hypomethylating agent-FLT3 inhibitor triplets and menin inhibitor combinations yielding high response rates with most patients achieving MRD negativity.
Post-transplant MRD-positive disease and relapse prevention: Strategies include chidamide-based MRD-driven therapy after allo-HSCT with an 88.5% MRD conversion rate from positive to negative, combination of pre-HSCT disease burden and early post-transplant minimal residual disease to predict survival, and the INTERCEPT multi-target, multi-arm platform trial for MRD relapse driven by NPM1mut, FLT3-ITD and KMT2A rearrangements.
Failure after venetoclax-hypomethylating agent therapy and need for targeted triplets: Among responders to HMAs plus venetoclax, 63 patients relapsed (59%) with median overall survival after relapse of 3.4 months (95% CI, 2.4, 6.7), with investigation of addition or alternative use of inhibitors of FLT3, IDH1, IDH2, or menin for patients with NPM1 or KMT2A rearrangements, and monotherapy targeting FLT3, IDH1/2, NPM1 or KMT2Ar for frail patients considered unfit for Ven-HMA.
REGAL Trial: Galinpepimut-S Delivers Significant Survival in AML
Venetoclax combined with low-dose cytarabine was evaluated in adults 60 years or older with previously untreated acute myeloid leukemia ineligible for intensive chemotherapy at venetoclax 600 mg per day orally in 28-day cycles with low-dose cytarabine 20 mg/m per day subcutaneously on days 1 to 10. Median age was 74 years (range, 63 to 90 years), with 49% secondary AML, 29% prior hypomethylating agent treatment, and 32% poor-risk cytogenetic features. Common grade 3 or greater adverse events were febrile neutropenia (42%), thrombocytopenia (38%), and WBC count decreased (34%), with early 30-day mortality of 6%. Fifty-four percent achieved complete remission/complete remission with incomplete blood count recovery with median time to first response of 1.4 months, median overall survival was 10.1 months (95% CI, 5.7 to 14.2), and median duration of response was 8.1 months (95% CI, 5.3 to 14.9 months). Among patients without prior hypomethylating agent exposure, complete remission/complete remission with incomplete blood count recovery was achieved in 62%, median duration of response was 14.8 months (95% CI, 5.5 months to not reached), and median overall survival was 13.5 months (95% CI, 7.0 to 18.4 months).
Ivosidenib monotherapy was evaluated at 500 mg daily in IDH1-mutated relapsed or refractory acute myeloid leukemia in a phase 1 dose-escalation and dose-expansion study in which 258 patients had safety outcomes assessed. Among 179 patients with relapsed or refractory disease, treatment-related adverse events of grade 3 or higher occurring in at least 3 patients were prolongation of the QT interval (in 7.8% of the patients), the IDH differentiation syndrome (in 3.9%), anemia (in 2.2%), thrombocytopenia or a decrease in the platelet count (in 3.4%), and leukocytosis (in 1.7%). In the primary efficacy population of 125 patients with at least 6 months of follow-up, the rate of complete remission or complete remission with partial hematologic recovery was 30.4% (95% confidence interval [CI], 22.5 to 39.3), the rate of complete remission was 21.6% (95% CI, 14.7 to 29.8), and the overall response rate was 41.6% (95% CI, 32.9 to 50.8). The median durations of these responses were 8.2 months (95% CI, 5.5 to 12.0), 9.3 months (95% CI, 5.6 to 18.3), and 6.5 months (95% CI, 4.6 to 9.3), respectively, transfusion independence was attained in 29 of 84 patients (35%), and among 34 patients who had a complete remission or complete remission with partial hematologic recovery, 7 (21%) had no residual detectable IDH1 mutations on digital polymerase-chain-reaction assay.
Ivosidenib in combination with azacitidine was evaluated in an open-label, multicenter, phase Ib trial in patients with newly diagnosed mutant IDH1 acute myeloid leukemia ineligible for intensive induction chemotherapy, using oral ivosidenib 500 mg once daily continuously with subcutaneous azacitidine 75 mg/m on days 1-7 in 28-day cycles in 23 patients with median age 76 years (range, 61-88 years). Treatment-related grade ≥ 3 adverse events occurring in > 10% of patients were neutropenia (22%), anemia (13%), thrombocytopenia (13%), and electrocardiogram QT prolongation (13%), with adverse events of special interest including all-grade IDH differentiation syndrome (17%), all-grade electrocardiogram QT prolongation (26%), and grade ≥ 3 leukocytosis (9%). Median treatment duration was 15.1 months (range, 0.3-32.2 months). The overall response rate was 78.3% (18/23 patients; 95% CI, 56.3% to 92.5%) and the complete remission rate was 60.9% (14/23 patients; 95% CI, 38.5% to 80.3%), with median duration of response in responders not reached at median follow-up of 16 months, 12-month survival estimate of 82.0% (95% CI, 58.8% to 92.8%), and mutant IDH1 clearance in bone marrow mononuclear cells by BEAMing digital polymerase chain reaction in 10/14 patients (71.4%) achieving complete remission.
Galinpepimut-S: A WT1-Targeting Immunotherapeutic with Broad Potential
Galinpepimut-S is a tetravalent, non-HLA restricted, heteroclitic Wilms Tumor 1 (WT1) peptide vaccine being investigated beyond acute myeloid leukemia in WT1-expressing solid tumors. Early-phase trials have focused on ovarian cancer and pleural mesothelioma, primarily in remission or post-treatment maintenance settings and in combination with checkpoint inhibition.
WT1-expressing ovarian cancer in second or third remission: evaluated in an open-label, non-randomized phase I study of sequential administration of galinpepimut-S with anti-PD-1 nivolumab. Therapy included six (every two weeks) subcutaneous inoculations of galinpepimut-S vaccine adjuvanted with Montanide, low-dose subcutaneous sargramostim at the injection site, with intravenous nivolumab over 12 weeks, and up to six additional doses until disease progression or toxicity.
Malignant pleural mesothelioma (MPM) after multimodality therapy: evaluated in a double-blind, controlled, two center phase II trial randomizing MPM patients after surgery and another treatment modality to galinpepimut-S with GM-CSF and Montanide or GM-CSF and Montanide alone.
Diffuse pleural mesothelioma (DPM) with progressive or recurrent disease after at least one course of pemetrexed-based chemotherapy: evaluated in an open-label, single-center phase 1 study combining galinpepimut-S with nivolumab. Patients received two doses of galinpepimut-S followed by six doses of galinpepimut-S with intravenous nivolumab every 2 weeks, and up to six additional cycles until disease progression or unacceptable toxicity.
Frequently Asked Questions
References
- [1] Abaza Y, Winer ES et al.. Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centers. American journal of hematology. 2024 Apr. 38342997
- [2] Jain N, Maiti A et al.. Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia. American journal of hematology. 2021 Aug 1. 33991360
- [3] Vives S, Martínez-Cuadrón D et al.. A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia. Cancer. 2021 Jun 15. 33626197
- [4] Jeurkar C, King L et al.. Management of Acute Myeloid Leukemia: A Review. Cancers. 2026 Feb 18. 41749912
- [5] Savaş EM, Bozkurt HH et al.. FLAMSA versus FLAG-IDA as salvage therapy in adults with relapsed/refractory acute myeloid leukemia and acute lymphoblastic leukemia: A single-center real-world retrospective study. Leukemia research. 2026 Aug. 42341445
- [6] Wirk B, Hawila R. The Impact of Induction With Azacitidine and Venetoclax Versus Intensive Chemotherapy on Outcomes After Allogeneic Hematopoietic Cell Transplantation for Newly Diagnosed Acute Myeloid Leukemia. Journal of hematology. 2026 Aug. 42730201
- [7] Magee GH, Grunwald MR. Updates on Therapy Options in Fit and Unfit Patients with Newly Diagnosed AML. Current treatment options in oncology. 2025 Sep. 40848224
- [8] Manning-Geist BL, Gnjatic S et al.. Phase I Study of a Multivalent WT1 Peptide Vaccine (Galinpepimut-S) in Combination with Nivolumab in Patients with WT1-Expressing Ovarian Cancer in Second or Third Remission. Cancers. 2023 Feb 25. 36900251
- [9] Serio B, Giudice V et al.. Efficacy of Decitabine and Venetoclax as Salvage and Bridge Therapy to Haploidentical Hematopoietic Stem Cell Transplantation in a Multiresistant Acute Myeloid Leukemia Patient. Case reports in oncology. 2022 May-Aug. 35949908
- [10] Girgis A, Breen S et al.. Impact of two supportive care interventions on anxiety, depression, quality of life, and unmet needs in patients with nonlocalized breast and colorectal cancers. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Dec 20. 19917842
- [11] Farina M, Malagola M et al.. Intensive Chemotherapy Versus Venetoclax-Based Regimens in Elderly Patients with Acute Myeloid Leukemia: Is the Chemotherapy Era Ending?. Journal of clinical medicine. 2025 Apr 17. 40283589
- [12] Ho VT, Vanneman M et al.. Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation. Proceedings of the National Academy of Sciences of the United States of America. 2009 Sep 15. 19717467
- [13] Jen WY, Croden J et al.. A Phase 2 study of CPX-351 in combination with venetoclax in patients with newly diagnosed high-risk acute myeloid leukemia. HemaSphere. 2025 Oct. 41132245
- [14] McMurry H, Fletcher L et al.. IDH Inhibitors in AML-Promise and Pitfalls. Current hematologic malignancy reports. 2021 Apr. 33939107
- [15] Ling W, Wu P et al.. MRD-driven HDACi-based therapy post-transplant: a real-world study in high-risk acute myeloid leukemia. Annals of hematology. 2026 Jul 13. 42439986
- [16] Wang L, Song J et al.. Comparison of venetoclax and ivosidenib/enasidenib for unfit newly diagnosed patients with acute myeloid leukemia and IDH1/2 mutation: a network meta-analysis. Journal of chemotherapy (Florence, Italy). 2024 May. 37599456
- [17] Cortes JE, Goldberg SL et al.. Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML. Cancer. 2015 Jan 15. 25223583
- [18] Myers L, Brereton TA et al.. Pediatric asthma management via integration of a remote spirometry device into an EHR-based artificial intelligence-powered clinical decision support system: A feasibility pragmatic clinical trial. Contemporary clinical trials. 2026 Feb. 41453519
- [19] Gangat N, Dinardo CD. Newly diagnosed acute myeloid leukemia in unfit patients: 2026 treatment algorithms. Blood cancer journal. 2025 Aug 16. 40818987
- [20] Bang SM, Kang KW et al.. Real-World Treatment Patterns and Clinical Outcomes in Korean Patients With AML Ineligible for First-Line Intensive Chemotherapy: A Subanalysis of the CURRENT Study, a Non-Interventional, Retrospective Chart Review. Journal of Korean medical science. 2023 Nov 13. 37967874
Contact Us
Address
350 Springfield Avenue,
Suite #200 Summit, NJ 07901
For General Inquiry
info@pienomial.com











